New insider activity at aTyr Pharma ( (ATYR) ) has taken place on October 9, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Paul Schimmel has made a significant investment in aTyr Pharma by purchasing 1,000,000 shares of the company’s stock. This transaction is valued at $905,899, indicating strong confidence in the company’s future prospects.
Recent Updates on ATYR stock
In the last 24 hours, aTyr Pharma’s stock has seen significant developments following the presentation of additional findings from the Phase 3 EFZO-FIT study of efzofitimod for pulmonary sarcoidosis. Despite demonstrating potential improvements in various health outcomes, the study failed to meet its primary endpoint, leading to a series of downgrades by analysts. RBC Capital and Wells Fargo both downgraded the stock due to the trial’s failure to show a significant reduction in corticosteroid use, with Wells Fargo expressing uncertainty about future FDA decisions. These developments have influenced the stock’s price target adjustments, reflecting concerns over the trial results and future regulatory outcomes.
Spark’s Take on ATYR Stock
According to Spark, TipRanks’ AI Analyst, ATYR is a Underperform.
The overall stock score for aTyr Pharma is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates bearish momentum, with the stock being oversold, which could suggest a potential for a short-term rebound. Valuation metrics are unfavorable due to negative earnings and lack of dividends.
To see Spark’s full report on ATYR stock, click here.
More about aTyr Pharma
YTD Price Performance: -74.42%
Average Trading Volume: 10,790,004
Technical Sentiment Signal: Sell
Current Market Cap: $81.95M